

SEQUENT SCIENTIFIC LIMITED
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER 2011

(Rs. in Lakhs)

S.No.	Particulars	STANDALONE				
		Quarter Ended		Half Year Ended		Year Ended
		30th Sep 2011 UNAUDITED	30th Sep 2010 UNAUDITED	30th Sep 2011 UNAUDITED	30th Sep 2010 UNAUDITED	31st Mar 2011 AUDITED
1	Net Sales / Income from Operations	8,919.40	7,080.40	15,780.90	13,355.20	25,775.57
	Other Operating Income	-	-	-	-	2,000.00
	Total Revenue	8,919.40	7,080.40	15,780.90	13,355.20	27,775.57
2	Expenditure					
a	(Increase)/Decrease in stock in Trade and work in progress	(621.20)	(811.10)	(410.30)	(1,170.10)	(1,291.44)
b	Consumption of Raw Materials	5,700.61	3,020.90	9,250.11	5,628.20	12,475.32
c	Purchase of Traded Goods	265.89	1,598.80	423.59	2,570.80	2,842.00
d	Conversion charges	196.38	259.25	415.97	504.45	1,161.42
e	Employee Cost	686.80	624.90	1,319.10	1,211.90	2,270.33
f	Depreciation	458.98	494.22	901.73	806.40	1,718.09
g	Other Expenditure	2,648.32	1,181.05	3,979.73	2,457.45	5,519.50
h	Total	9,335.78	6,368.02	15,879.93	12,009.10	24,695.22
3	Profit/(Loss) from Operations before other income, interest and exceptional items.	(416.38)	712.38	(99.03)	1,346.10	3,080.35
4	Other Income	99.40	273.20	674.60	390.50	1,163.39
5	Profit/(Loss) before interest & exceptional Items	(316.98)	985.58	575.57	1,736.60	4,243.74
6	Financial cost	702.20	474.00	1,399.80	883.60	2,127.54
7	Profit/(Loss) after interest but before exceptional Items	(1,019.18)	511.58	(824.23)	853.00	2,116.20
8	Exceptional items	-	(524.80)	-	(524.80)	(105.26)
9	Profit/(Loss) from ordinary activities before tax	(1,019.18)	1,036.38	(824.23)	1,377.80	2,221.46
10	Tax Expense	31.17	181.00	176.24	259.00	628.33
11	Net Profit/(Loss) from Ordinary activities after tax	(1,050.35)	855.38	(1,000.47)	1,118.80	1,593.13
12	Extraordinary items	-	-	-	-	-
13	Net Profit	(1,050.35)	855.38	(1,000.47)	1,118.80	1,593.13
14	Paid-up equity share capital (Face Value per share Rs.10 each)	2,123.50	2,123.50	2,123.50	2,123.50	2,123.50
15	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year					11,151.90
16	Earnings Per Share before Extraordinary Items for the period (Non-Annualised)					
	Basic (Rs.)	(4.79)	3.90	(4.56)	5.10	7.26
	Diluted (Rs.)	(4.79)	3.90	(4.56)	5.10	7.26
	Earnings Per Share after Extraordinary Items for the period (Non-Annualised)					-
	Basic (Rs.)	(4.79)	3.90	(4.56)	5.10	7.26
	Diluted (Rs.)	(4.79)	3.90	(4.56)	5.10	7.26
17	Public Share Holding					
	No. of Shares	6,028,969	6,687,557	6,028,969	6,687,557	6,028,969
	% of Share Holding	27.49%	30.49%	27.49%	30.49%	27.49%
18	Promoters and Promoter Group Shareholding					
	a) Pledged / Encumbered					
	1. No of shares	10,300,000	1,300,000	10,300,000	1,300,000	2,300,000
	2. Percentage of shares(as a % of the total shareholding of promoter & promoter group)	64.75%	8.53%	64.75%	8.53%	14.46%
	3. Percentage of shares (as a % of the total share capital of the company)	46.96%	5.93%	46.96%	5.93%	10.49%
	b) Non-encumbered					
	1. No of shares	5,606,222	13,947,634	5,606,222	13,947,634	13,606,222
	2. Percentage of shares(as a % of the total shareholding of promoter & promoter group)	35.25%	91.47%	35.25%	91.47%	85.54%
	3. Percentage of shares (as a % of the total share capital of the company)	25.55%	63.58%	25.55%	63.58%	62.02%

Statement of Assets and Liabilities as at

S.No.	Particulars	30th Sep 2011 UNAUDITED	30th Sep 2010 UNAUDITED	31st Mar 2011 AUDITED
A	SOURCES OF FUNDS			
	1. Shareholders' Fund			
	(a) Capital	2,123.50	2,123.50	2,123.50
	(b) Employees stock options outstanding	0.70	-	0.70
	(c) Reserves and Surplus	9,459.30	10,329.40	10,431.10
	2. Loan Funds			
	(a) Secured	15,404.80	15,318.10	15,965.40
	(b) Unsecured	3,348.20	691.60	1,620.00
	3. Deferred Tax Liabilities	1,395.31	940.20	1,229.11
	Total	31,731.81	29,402.80	31,369.81
B	APPLICATION OF FUNDS			
	1. Fixed Assets	21,122.10	20,453.60	21,791.20
	2. Investments	1,375.51	1,488.60	1,389.12
	3. Current Assets			
	(a) Inventories	6,414.70	5,249.50	6,147.00
	(b) Sundry Debtors	7,670.40	7,278.10	6,430.09
	(c) Cash and Bank Balances	1,049.10	398.60	680.30
	(d) Loans and Advances	8,453.10	6,285.90	6,650.40
	4. Current Liabilities and Provisions			
	(a) Current Liabilities	11,786.30	9,355.10	9,134.30
	(b) Provisions	2,566.80	2,396.40	2,584.00
	Net Current Assets	9,234.20	7,460.60	8,189.49
	Total	31,731.81	29,402.80	31,369.81

Notes:

- The unaudited financial results were taken on record by the Board of Directors at its meeting held on October 21, 2011.
- The Statutory Auditors have performed a limited review of the standalone financial results for the period ended as on September 30, 2011 of the Company as required by Clause 41 of the Listing Agreement.
- On 1 June 2011 the Company transferred certain leasehold land, building, and other assets on a slump sale basis to its associate Sequent Penems Private Limited for a total consideration of Rs. 900 Lakhs. The profit arising out of the sale amounting to Rs. 502.7 lakhs has been included in Other Income during the half year ended 30 September 2011. The Company has subsequently received approval from Karnataka Industrial Areas Development Board (KIADB) with respect to the transfer of the leasehold land.
- The Scheme of Amalgamation of Fraxis Life Sciences Limited ("Transferor Company") with the Company ("Transferee Company") has been sanctioned by the High Court of Bombay on August 20, 2011 with the appointed date and effective date being September 14, 2011, the date on which the sanctioned Scheme is filed by the Company with the Registrar of Companies, Mumbai ("the Scheme"). In terms of the Scheme:
 - The amalgamation has been accounted for under the Purchase Method of accounting as specified in Accounting Standard (AS) – 14 Accounting for Amalgamations, notified by the Central Government of India under the Companies (Accounting Standards) Rules, 2006.
 - All the assets and liabilities of the Transferor Company have been recorded by the Transferee Company at their respective carrying amounts as appearing in the books of the Transferor Company as on the appointed date.
 - The investment in the equity share capital of the Transferee Company as appearing in the books of accounts of the Transferor Company stands cancelled and accordingly, the share capital of the Transferee Company shall stand reduced to the extent of face value of shares held by the Transferor Company in the Transferee Company as on the appointed date.
 - In accordance with the scheme, the Board of Directors of the Transferee Company have approved the issue and allotment of 14,865,000 number of equity shares at par of the Transferee Company to the respective shareholders of the Transferor Company in the proportion of their shareholding in the Transferor Company. The Company is in the process of cancelling the shares held by the Transferor Company and allotting shares to the respective shareholders of the Transferor Company.
 - The excess of the value of the net assets of the Transferor Company acquired by the Transferee Company over the face value of the shares issued by the Transferee Company as consideration to the shareholders of the Transferor Company and after adjusting for cancellation of equity share capital as mentioned in c above is treated as Capital Reserve amounting to Rs.62.43 Lakhs (net of merger expenses).
 - All costs, charges, taxes including duties, levies and all other expenses, if any arising out of, or incurred in carrying out and implementing the Scheme and to put it into operation has been borne by the Transferee Company and has been adjusted against the Capital Reserve.
- During the year ended March 31, 2011 the Scheme of amalgamation of Vedic Elements Private Limited ("Transferor Company") with the Company ("Transferee Company") with an appointed date of October 1, 2009. ("The Scheme"), was sanctioned by the High Court of Karnataka and came into effect on 07 September 2010. In terms of the Scheme:
 - Upon the scheme becoming effective, the assets and liabilities of the Transferee Company have been revalued based on valuation report or fair value determined by the Board of Directors of the Company and the net surplus of Rs.3,410.8 lakhs arising out of such valuations (over the carrying value of the respective assets and liabilities prior to the valuation) have been credited to the Restructuring Reserve account.
 - The deficit arising on amalgamation of Rs.3,370.2 lakhs representing the value of assets over the value of liabilities of the Transferor Company, after cancellation of capital of the transferor Company and the reserves recorded has been set-off against Restructuring reserve account.
 - Had the Scheme not provided for fair valuing the assets and liabilities of the Transferee Company, the effect of accounting as per the Accounting standards issued under the Companies (Accounting Standards) Rules, 2006 for the previous year ended March 31,2011, would have been as under:
 - Depreciation expenses would have been lower by Rs.81. 6 lakhs, provision for 'Other than temporary impairment in investments' would have been higher by Rs.347.8 lakhs. Decrease in income from exceptional item lower by Rs.575 lakhs. The resultant impact on profit after tax for the year ended March 31, 2011 being lower by Rs.841.2 lakhs.
 - Earning Per Share (EPS) (Face Value of Rs.10 each)

	Year Ended 31-Mar-11
Basic (Rs.)	3.43
Diluted (Rs.)	3.43
- During the quarter there was an accident at the Tarapur plant of the Company arising due to leakage of Hydrogen Sulphide gas. Investigations by the regulatory authorities is on going but the Company does not expect any negative findings as a result of such investigations. The Plant has subsequently commenced operations.
- Details of investor complaints for the quarter ended 30th Sep 2011:

Unresolved at the beginning of the quarter :	Nil
Received during the quarter :	Nil
Disposed off during the quarter :	Nil
Unresolved at the end of quarter :	Nil

8. Segment Results

The company has identified Pharmaceuticals and Speciality Chemicals as its business segments, Segments have been identified taking in to account the nature of products, the differing risks & returns, the organisational structure & the internal reporting system.

Sl. No	Particulars	Quarter Ended		Half Year Ended		Year Ended
		30th Sep 2011 UNAUDITED	30th Sep 2010 UNAUDITED	30th Sep 2011 UNAUDITED	30th Sep 2010 UNAUDITED	31st Mar 2011 AUDITED
1	Segment Revenue					
	a) Pharmaceuticals	7,715.38	6,068.57	13,582.93	11,389.07	23,782.24
	b) Speciality Chemicals	1,204.02	1,210.60	2,197.97	2,261.66	5,254.79
	Total	8,919.40	7,279.17	15,780.90	13,650.73	29,037.03
	Less: Intersegment Revenue	-	198.77	-	295.53	1,261.46
	Net Sales /Income from Operations	8,919.40	7,080.40	15,780.90	13,355.20	27,775.57
2	Segment Results					
	Profit or Loss before Tax and Interest from Each Segment					
	a) Pharmaceuticals	154.86	813.57	488.99	1,463.27	3,361.10
	b) Speciality Chemicals	157.60	310.08	408.40	596.79	1,212.86
	Total	312.46	1,123.65	897.39	2,060.06	4,573.96
	Less (i) Finance Cost	702.15	473.95	1,399.79	883.56	2,127.50
	(ii) other unallocable expenditure net off unallocable income	629.49	(386.68)	321.83	(201.30)	225.00
	Total Profit Before Tax	(1,019.18)	1,036.38	(824.23)	1,377.80	2,221.46
3	Capital Employed					
	a) Pharmaceuticals	42,048.46	38,427.83	42,048.46	38,427.83	41,437.30
	b) Speciality Chemicals	2,578.88	4,061.06	2,578.88	4,061.06	3,388.40
	c)Unallocated	(12,895.53)	(13,086.09)	(12,895.53)	(12,295.09)	(13,455.89)
	Total	31,731.81	29,402.80	31,731.81	30,193.80	31,369.81

9. Figures for previous periods may have been regrouped and rearranged, wherever necessary, to conform to the relevant current period classification.

For Sequent Scientific Limited

Place: Bangalore
Date : October 21, 2011

K.R.Ravishankar
Chairman & Managing Director